Peptide receptor radionuclide treatment in an outpatient setting – A single center experience

#4136

Introduction: Peptide receptor radionuclide therapy (PRRT) is an important treatment option for somatostatin receptor expressing non-resectable neuroendocrine tumors. Traditionally, this therapy has been provided as inpatient care. PRRT has been offered by Oslo University Hospital from November 2019, and organized mainly as outpatient care.

Aim(s): To explore experience from the first 4 years of providing PRRT in an outpatient setting.

Materials and methods: A total of 118 patients received 392 PRRT treatments with 177-Lu-DOTATATE from Nov 2019 to Oct 2023. Ninety patients had 324 therapies as a first cycle treatment, 30 patients had 62 salvage PRRT therapies in a second cycle, and one patient has received two treatments in a third cycle.

Conference:

Presenting Author:

Authors: Sponheim J, Dahle V, Skrede Mordal K, Solberg H, Åvitsland T,

Keywords: PRRT, outpatient care,